MC# 19-10 - A Phase Ib Study of ARQ 751 as a Single Agent or in Combination with Other Anti-cancer Agents in Adult Subjects with Advanced Solid Tumors with PIK3CA/AKT/PTEN Mutations
Agent(s): ARQ 751
Disease Type(s): Solid Tumor
Drug Classification(s): Targeted Therapy, Small Molecule
Molecular Target(s): AKT, PIK3CA, PTEN
Mechanism of Action
ARQ 751 is a potent and selective allosteric AKT inhibitor that suppresses the AKT pathway via two modes of action. First, it binds to the inactive form of AKT and prevents membrane localization and full AKT activation. Second, it also directly inhibits the membrane associated active form of AKT.
In this study, the sponsor and investigators want to learn:
- How much of ARQ 751 can be given with an acceptable level of side effects when given in combination with Paclitaxel or Fulvestrant
- The effects of ARQ 751 (good and bad) when given alone or in combination with Paclitaxel or Fulvestrant
- How much of ARQ 751 is absorbed into the blood and how fast it is removed when given alone or in combination with Paclitaxel or Fulvestrant
- 18 years of age and older
- Histologically and/or cytologically documented diagnosis of a selected tumor type that is locally advanced, inoperable, metastatic or recurrent (including but not restricted to breast cancer, TNBC [triple negative]; HR-positive [HR+]/HER2-negative [HER2-] or endometrial cancer)
- Documented PIK3CA, AKT or known actionable PTEN mutations by genetic testing
- For Arms B or C, eligible for paclitaxel or fulvestrant therapy as per Investigator assessment
- Failure to respond to standard therapy, or for whom standard or curative therapy does not exist or is not tolerable.
- No more than 3 prior systemic regimens for the advanced disease with confirmed disease progression
- Neoadjuvant and adjuvant chemotherapy are considered one regimen if they are a continuation of the same regimen with interval debulking surgery
- If the subject is refractory or has disease progression within 6 months after completion of the adjuvant treatment, then the adjuvant treatment should be considered as the line of treatment rather than an adjuvant therapy.
- Endocrine (hormonal) therapy does not count toward total lines of therapy
- Maintenance therapy is considered part of the preceding regimen if one or more of the same drugs are continued
- Has at least one measurable target lesion according to RECIST v. 1.1
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 1
- Adequate organ function as indicated by the following laboratory values:
- Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
- Platelet count (Plt) ≥ 100 x 109/L
- Hemoglobin (Hb) ≥ 9 g/dL
- International normalized ratio (INR) 0.8 to upper limit of normal (ULN) or ≤ 3 for subjects receiving anticoagulant therapy such as Coumadin or heparin
- Serum creatinine ≤ 1.5 x ULN or calculated creatinine clearance ≥ 60 mL/min/1.73 m2 for subjects with serum creatinine levels > 1.5 x institutional ULN
- Total bilirubin ≤ 1.5 x ULN
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x ULN or ≤ 5 x ULN for subjects with known liver metastases
- Glycated hemoglobin (HbA1c) ≤ 8% (≤ 64 mmol/mol)
- If a subject is currently receiving bisphosphonates or any other drug for treatment of osteoporosis, treatment-induced bone loss and metastases to bone, the subject must have received the bisphosphonates for at least four weeks prior to the first dose of study treatment.
- Initiation of bisphosphonates or similar agents during the study may be allowed provided the subject completes the first cycle of treatment without any dose limiting toxicity (DLT) and the Investigator rules out tumor progression.
- Male or female subjects of child-producing potential must agree to use double-barrier contraceptive measures, oral contraception, or avoidance of intercourse during the study and for 90 days after the last dose of study treatment.
- Women of childbearing potential must have a negative serum pregnancy test during Screening Period and within 48 hours of the first dose of study treatment. “Women of childbearing potential” is defined as sexually mature women who have not undergone a hysterectomy or who have not been naturally postmenopausal for at least 12 consecutive months prior to the first dose of study treatment.
- Anti-cancer therapy, such as chemotherapy, immunotherapy, hormonal therapy, targeted therapy, or investigational agents within five half-lives or four weeks, whichever is shorter, prior to administration of the first dose of study treatment (five half-lives or six weeks, whichever is shorter)
- To be eligible for study treatment, toxicity from prior treatment(s) must recover to Grade ≤ 1, except for alopecia
- Concurrent systemic high-dose corticosteroids (in dosing exceeding 10 mg QD of prednisone equivalent) when used intermittently in an antiemetic regimen, for central nervous system (CNS) metastases management, or as a part of the premedication regimen are allowed
- Radiation therapy within four weeks, or palliative radiation therapy within two weeks, prior to administration of the first dose of study treatment
- To be eligible for study treatment, radiation therapy-related toxicity must recover to Grade ≤ 1 prior to administration of the first dose of study treatment
- Concurrent palliative radiotherapy for local pain-control or prevention of fracture (for known bone metastases) may be allowed provided the subject completes the first cycle of treatment, does not meet criteria of progressive disease, and treated lesions will not be included in the target/non-target lesion assessment.
- Major surgical procedure within four weeks prior to administration of the first dose of study treatment
- To be eligible for the study treatment, all surgical wounds must be fully healed, and any surgery-related adverse events must recover to Grade ≤ 1.
- Unable or unwilling to swallow the complete daily dose of ARQ 751
- Previous treatment with:
- AKT inhibitors (e.g., ARQ 092, MK-2206, GSK2141795, AZD5363; prior treatment with PI3K or mTOR inhibitor are allowed)
- Prior taxane therapy for the advanced, metastatic disease
- Known prior allergic reaction to or severe intolerance of paclitaxel, fulvestrant or PARP inhibitors (e.g., olaparib, niraparib). Intolerance is defined as a serious adverse event, a grade 3 or 4 AE per CTCAE v.4.03, or permanent treatment discontinuation
- History of Type 1 or 2 diabetes mellitus requiring regular medication (other than oral hypoglycemic agents) or fasting glucose ≥ 160 mg/dL at Screening visit.
- Significant gastrointestinal disorder(s) that could, in the opinion of the Investigator, interfere with the absorption, metabolism, or excretion of ARQ 751 (e.g., inflammatory bowel disease, Crohn’s disease, ulcerative colitis, extensive gastric resection)
- Known untreated or active CNS metastases and/or carcinomatous meningitis
- To be eligible for the study treatment, subjects must have stable disease ≥ 1 month, confirmed by magnetic resonance imaging (MRI) or computed tomography (CT) scan, and have CNS metastases well controlled by low-dose steroids, anti-epileptics, or other symptom-relieving medications.
- History of myocardial infarction (MI) or New York Heart Association (NYHA) Class II-IV congestive heart failure within 6 months of the administration of the first dose of study treatment (MI occurring > 6 months of the first dose of study treatment will be permitted); Grade 2 or worse conduction defect (e.g., right or left bundle branch block).
- A heart rate corrected QT (QTc) interval ≥ 480 msec, using the Fridericia's formula QTcF
- Left ventricular ejection fraction (LVEF) <50% as determined by Multiple Gated Acquisition (MUGA) scan or echocardiogram (ECHO) in subjects who received prior treatment with anthracyclines
- Concurrent severe and/or uncontrolled illness not related to cancer and/or social situation that would limit compliance with study requirements, including but not limited to:
- Psychiatric illness, substance abuse
- Ongoing or active known infection, including human immunodeficiency virus (HIV) infection, hepatitis B or C virus
- Significant pulmonary dysfunction, including pneumonitis, interstitial lung disease (ILD), idiopathic pulmonary fibrosis, cystic fibrosis, severe COPD
- Peripheral neuropathy grade ≥2 (Arm B, ARQ 751+paclitaxel)
- Bleeding diathesis, thrombocytopenia or coagulation disorders (Arm C, ARQ 751+fulvestrant)
- Thrombotic/coagulation disorders within 6 months prior to the first dose of study treatment unless stable on anticoagulation for > 3 months
- Active or history of other malignancy other than the current cancer within 2 years of the first dose of study treatment, with the exception of carcinoma in-situ of the cervix, basal cell carcinoma, and superficial bladder tumors curatively treated
- Blood transfusion or administration of growth factors within 5 days prior to a blood draw being used to confirm eligibility
- Pregnant or breastfeeding
- Dallas, TX - Mary Crowley Cancer Research - Medical City